Literature DB >> 23749887

Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma.

Ying-Jen Jeffrey Wu1, Alexander J Neuwelt, Leslie L Muldoon, Edward A Neuwelt.   

Abstract

BACKGROUND: Ovarian cancer is commonly treated with cisplatin/paclitaxel but many tumors become resistant. Acetaminophen reduced glutathione and enhanced chemotherapy efficacy in hepatic cancer treatment. The objective of this study was to examine if acetaminophen enhances the cytotoxicity of cisplatin/paclitaxel in ovarian cancer.
MATERIALS AND METHODS: SKOV3 human ovarian carcinoma cells in vitro and a subcutaneous tumor nude rat model were used and treated with cisplatin/paclitaxel with or without acetaminophen.
RESULTS: In vitro, acetaminophen enhanced apoptosis induced by cisplatin and paclitaxel with similar effects on glutathione, reactive oxygen species and mitochondrial membrane potential, but different effects on nuclear factor erythroid 2-related factor 2 (NRF2) translocation. In vivo, acetaminophen was uniformly distributed in tissues and significantly reduced hepatic glutathione. Acetaminophen enhanced the cisplatin chemotherapeutic effect by reducing tumor recurrence.
CONCLUSION: Our results suggest that acetaminophen as a chemoenhancing adjuvant could improve the efficacy of cisplatin and paclitaxel in treating patients with ovarian carcinoma and other tumor types.

Entities:  

Keywords:  Acetaminophen; SKOV3 cells; chemo-enhancement; cisplatin; glutathione; ovarian cancer

Mesh:

Substances:

Year:  2013        PMID: 23749887      PMCID: PMC3709593     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  50 in total

1.  Effect of Taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone.

Authors:  V E Kostrubsky; L D Lewis; S G Wood; P R Sinclair; S A Wrighton; J F Sinclair
Journal:  Toxicol Appl Pharmacol       Date:  1997-01       Impact factor: 4.219

Review 2.  Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.

Authors:  M Gosland; B Lum; J Schimmelpfennig; J Baker; M Doukas
Journal:  Pharmacotherapy       Date:  1996 Jan-Feb       Impact factor: 4.705

3.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.

Authors:  Tanya J Shaw; Mary K Senterman; Kerri Dawson; Colleen A Crane; Barbara C Vanderhyden
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

4.  Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.

Authors:  E Harnagea-Theophilus; S L Gadd; A H Knight-Trent; G L DeGeorge; M R Miller
Journal:  Toxicol Appl Pharmacol       Date:  1999-03-15       Impact factor: 4.219

5.  Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.

Authors:  A L Vahrmeijer; J H van Dierendonck; J Schutrups; C J van de Velde; G J Mulder
Journal:  Biochem Pharmacol       Date:  1999-08-15       Impact factor: 5.858

6.  The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.

Authors:  Y Jeffrey Wu; Leslie L Muldoon; Edward A Neuwelt
Journal:  J Pharmacol Exp Ther       Date:  2004-10-20       Impact factor: 4.030

7.  Taxol induces caspase-10-dependent apoptosis.

Authors:  Soo-Jung Park; Ching-Haung Wu; John D Gordon; Xiaoling Zhong; Armaghan Emami; Ahmad R Safa
Journal:  J Biol Chem       Date:  2004-09-27       Impact factor: 5.157

Review 8.  Mechanisms of drug resistance in ovarian cancer.

Authors:  S W Johnson; R F Ozols; T C Hamilton
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860

Review 9.  Promising new therapies in the treatment of advanced ovarian cancer.

Authors:  C D Runowicz; A L Fields; G L Goldberg
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

Review 10.  Taxol (paclitaxel): mechanisms of action.

Authors:  S B Horwitz
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

View more
  12 in total

1.  High αv Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats.

Authors:  Yingjen Jeffrey Wu; Michael A Pagel; Leslie L Muldoon; Rongwei Fu; Edward A Neuwelt
Journal:  Anticancer Res       Date:  2017-08       Impact factor: 2.480

2.  Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells.

Authors:  Jiaxi Yao; Yue Liu; Jitao Yang; Mengling Li; Simin Li; Bo Zhang; Rui Yang; Yuchong Zhang; Xiaoyu Cui; ChunQing Feng
Journal:  Front Genet       Date:  2022-06-03       Impact factor: 4.772

3.  Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Authors:  Stephen H Bush; Sharon Tollin; Douglas C Marchion; Yin Xiong; Forough Abbasi; Ingrid J Ramirez; Nadim Bou Zgheib; Bernadette Boac; Patricia L Judson; Hye Sook Chon; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Anders E Berglund; Laura J Havrilesky; Johnathan M Lancaster
Journal:  Mol Clin Oncol       Date:  2016-01-07

4.  Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation.

Authors:  Yung-Luen Yu; Giou-Teng Yiang; Pei-Lun Chou; Hsu-Hung Tseng; Tsai-Kun Wu; Yu-Ting Hung; Pei-Shiuan Lin; Shu-Yu Lin; Hsiao-Chun Liu; Wei-Jung Chang; Chyou-Wei Wei
Journal:  Mol Med Rep       Date:  2014-03-28       Impact factor: 2.952

5.  Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.

Authors:  P Ambady; Y J Wu; J M Walker; C Kersch; M A Pagel; R L Woltjer; R Fu; L L Muldoon; E A Neuwelt
Journal:  Cancer Gene Ther       Date:  2017-07-28       Impact factor: 5.987

6.  Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity.

Authors:  Shouyong Li; Yanlei Wei
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

7.  Chemoresistance to Cancer Treatment: Benzo-α-Pyrene as Friend or Foe?

Authors:  Kevin Dzobo; Naseeha Hassen; Dimakatso Alice Senthebane; Nicholas Ekow Thomford; Arielle Rowe; Hendrina Shipanga; Ambroise Wonkam; M Iqbal Parker; Shaheen Mowla; Collet Dandara
Journal:  Molecules       Date:  2018-04-17       Impact factor: 4.411

Review 8.  Glutathione in Ovarian Cancer: A Double-Edged Sword.

Authors:  Sofia C Nunes; Jacinta Serpa
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

9.  The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.

Authors:  Hannah J Gleneadie; Amy H Baker; Nikolaos Batis; Jennifer Bryant; Yao Jiang; Samuel J H Clokie; Hisham Mehanna; Paloma Garcia; Deena M A Gendoo; Sally Roberts; Megan Burley; Alfredo A Molinolo; J Silvio Gutkind; Ben A Scheven; Paul R Cooper; Joanna L Parish; Farhat L Khanim; Malgorzata Wiench
Journal:  Cancer Lett       Date:  2021-01-05       Impact factor: 8.679

Review 10.  Targeting Nrf2 may reverse the drug resistance in ovarian cancer.

Authors:  Danjie Li; Xiaoling Hong; Feijie Zhao; Xinxin Ci; Songling Zhang
Journal:  Cancer Cell Int       Date:  2021-02-17       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.